Givastomig Data Will Be Presented at ESMO Congress
New clinical findings for a gastric cancer treatment will be shared with the medical community this October.
Updated on Oct. 8, 2026 in Cancer
Live Poll
Does the announcement of new clinical trial data increase your trust in cancer research progress?
NovaBridge Biosciences will present updated clinical data on givastomig at the European Society for Medical Oncology (ESMO) Congress in Madrid. The presentation, scheduled for October 25, 2026, highlights the development of the therapy for patients with advanced gastroesophageal adenocarcinoma.
Why it matters
The study evaluates a potential new approach for treating HER2-negative metastatic gastroesophageal adenocarcinoma, a condition for which the FDA has granted givastomig Fast Track Designation. This progress marks a step toward possible registrational development in first-line cancer care.
Researchers are evaluating givastomig in a global randomized Phase 2 trial alongside nivolumab and chemotherapy, with results expected in late October 2026. The findings remain preliminary until the formal presentation at the ESMO Congress.
The players
NovaBridge Biosciences
A biotechnology company focused on developing novel bispecific antibody therapies for oncology.
Samuel J. Klempner
An oncology researcher specializing in gastrointestinal cancers and clinical trial design.
U.S. Food and Drug Administration
The federal agency responsible for regulating pharmaceuticals and granting special designations to accelerate drug development.
The details
Givastomig functions as a bispecific antibody targeting Claudin 18.2 and 4-1BB. By conditionally activating T cells via the 4-1BB signaling pathway specifically within the tumor microenvironment, the therapy is designed to focus the immune system on cancer cells while potentially minimizing systemic effects. This trial investigates the drug when used in combination with standard nivolumab and chemotherapy regimens.
Timeline
The ESMO Congress 2026 takes place from October 23 to October 27, 2026.
Samuel J. Klempner will present the givastomig study data on October 25, 2026.
Health Landscape
The development of givastomig reflects a broader trend in oncology toward utilizing bispecific antibodies that selectively activate the immune system within tumor sites. This approach aims to improve outcomes in advanced gastroesophageal adenocarcinoma, a space that currently relies heavily on standard chemotherapy and immune checkpoint inhibitors.
As this study involves an investigational therapy currently in the clinical trial phase, it is not yet available as a standard treatment option. Patients with gastroesophageal adenocarcinoma who are interested in trial eligibility should consult with their oncology team about ongoing research opportunities.
The takeaway
This news highlights an ongoing attempt to improve first-line treatment options for patients with advanced gastric cancers. Patients should discuss the potential role of clinical trials and new immunotherapy targets with their physician to understand if emerging research might be relevant to their care.
Further reading
For more information on current treatment trends, visit our Cancer section.
Live Poll
Does the announcement of new clinical trial data increase your trust in cancer research progress?
